Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis
Open Access
- 30 April 2021
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 100 (17), e25622
- https://doi.org/10.1097/md.0000000000025622
Abstract
Objectives: To evaluate the efficacy of double-filtration plasmapheresis (DFPP) treatment of myasthenia gravis (MG) through a systematic review and meta-analysis. Methods: PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wanfang databases were searched for randomized controlled trials (RCTs) and clinical controlled trials (CCTs) on DFPP for MG from database establishment to June 2019. Two researchers independently screened the articles, extracted the data, and cross checked the results. RevMan 5.3 was used for statistical analyses. Results: Seven RCTs and 2 CCTs were found comprising 329 patients. The results showed that clinical MG remission rate after DFPP treatment was significantly higher (OR = 4.33; 95% confidence interval [CI], 1.97–9.53; P < .001) and the serum levels of antititin antibody was significantly decreased (standardized mean difference [SMD] = 9.30; 95% CI, 7.51–11.08; P < .001). In addition, the quantitative MG (QMG) score, hospital stay and time to remission of MG symptoms, and acetylcholine receptor antibody (AchRAb) decreased in the DFPP treatment group; however, these outcomes had high heterogeneity among the studies. Only one study has reported on the adverse effects, including hypotension and hematoma. Conclusion: This meta-analysis suggests that DFPP can be recommended for the short-term mitigation of MG. Because our review was limited by the quantity and quality of the included studies, the above conclusions should be verified by additional high-quality studies.Funding Information
- Shijiazhuang Science and Technology Bureau Foundation (Grant no. 171461553/151461303)
- Key Research of Medical Science Research of Hebei Province (20170981)
This publication has 31 references indexed in Scilit:
- A Decrease in the Percentage of CD3+ Cells Is Correlated With Clinical Improvement During Plasmapheresis in Patients With Myasthenia GravisArtificial Organs, 2012
- Comparative analysis of therapeutic options used for myasthenia gravisAnnals of Neurology, 2010
- Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late‐onset Myasthenia GravisTherapeutic Apheresis and Dialysis, 2010
- Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravisAutoimmunity, 2010
- Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravisEuropean Journal of Neurology, 2009
- Myasthenia gravis: clinical, immunological, and therapeutic advancesActa Neurologica Scandinavica, 2005
- Myasthenia Gravis in Individuals over 40Annals of the New York Academy of Sciences, 2003
- Predicting the course of myasthenic weakness following double filtration plasmapheresisActa Neurologica Scandinavica, 2003
- Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis: A study of IgG subclasses and clinical correlationsJournal of Neuroimmunology, 2000
- Reliability Testing of the Quantitative Myasthenia Gravis ScoreaAnnals of the New York Academy of Sciences, 1998